The overall objective of this proposal is to determine the impact of the new Haemophilus conjugate vaccines on Haemophilus influenzae type b disease in Minnesota and in Dallas County, Texas. One of the new conjugate Haemophilus vaccines currently licensed for use in U.S. children greater than or equal to 18 months of age provided significant protection against Haemophilus disease in Finnish infants, but not in native Alaskan infants. These results suggest that host or environmental factors affect the efficacy of Haemophilus vaccines. In Minnesota and Dallas County there are regional differences in : 1) the age-specific incidence of Haemophilus disease; 2) the protective efficacy achieved in children vaccinated with the first generation Haemophilus type b polysaccharide vaccines; and 3) the risk of primary Hib disease in children attending day care. These differences provide a unique opportunity to further our understanding of factors that affect the epidemiology of Haemophilus disease.
In Aim 1, we will perform a case-control study to measure the protective efficacy of the new Haemophilus conjugate vaccines as they are introduced in the study areas. We will monitor the impact of these vaccines on the incidence of Haemophilus disease through active disease surveillance that achieves a high degree of case ascertainment.
In Aim 2, we will complete case-control studies determining the risk of primary haemophilus disease in children attending day care facilities, and we will assess the contribution of certain day care characteristics and practices to the risk of disease.
In Aim 3, we will investigate the immune responses of infants 2 and 12 months of age vaccinated with the new conjugate Haemophilus vaccines, comparing the responses of infants by type of conjugate vaccine, age at vaccination and geographic area. Immune responses will be determined by several methods including total and isotype-specific antibody responses, complement mediated bactericidal activity and opsonic activity. The result of these studies will allow us to assess the effectiveness of the conjugate vaccines in preventing disease in our study areas. They also may permit us to describe immunologic factors responsible for differences in protective efficacy observed with Haemophilus vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI021842-04
Application #
3132242
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Project Start
1986-09-01
Project End
1994-11-30
Budget Start
1989-12-01
Budget End
1990-11-30
Support Year
4
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Minneapolis Health & Family Support Department
Department
Type
DUNS #
City
Minneapolis
State
MN
Country
United States
Zip Code
55415
Kantor, E; Luxenberg, J S; Lucas, A H et al. (1997) Phase I study of the immunogenicity and safety of conjugated Hemophilus influenzae type b vaccines in the elderly. Vaccine 15:129-32
Murphy, T V; Pastor, P; Medley, F (1997) Factors associated with unnecessary immunization given to children. Pediatr Infect Dis J 16:47-52
Levine, O S; Granoff, D M; Lagos, R et al. (1997) Factors associated with superior antibody responses to a single dose of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age. Vaccine 15:325-8
Lucas, A H; Granoff, D M (1995) Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates. J Immunol 154:4195-202
Murphy, T V; Pastor, P; Turner, S B et al. (1995) Estimating immunization coverage from school-based childhood immunization records. Pediatr Infect Dis J 14:561-7
Granoff, D M; Lucas, A H (1995) Laboratory correlates of protection against Haemophilus influenzae type b disease. Importance of assessment of antibody avidity and immunologic memory. Ann N Y Acad Sci 754:278-88
Granoff, D M; Holmes, S J; Belshe, R B et al. (1994) Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. JAMA 272:1116-21
Granoff, D M; Shackelford, P G; Holmes, S J et al. (1993) Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates. Description of a new lambda light chain-associated idiotype and the relation between idiotype expression, avid J Clin Invest 91:788-96
Granoff, D M; Rathore, M H; Holmes, S J et al. (1993) Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 11 Suppl 1:S46-51
Lucas, A H; Azmi, F H; Mink, C M et al. (1993) Age-dependent V region expression in the human antibody response to the Haemophilus influenzae type b polysaccharide. J Immunol 150:2056-61

Showing the most recent 10 out of 36 publications